Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases

References

• HimelsteinAL, FosterJC, KhatcheressianJL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48–58. doi:10.1001/jama.2016.1942528030702
   PubMed Web of Science ®Google Scholar
• WaningDL, MohammadKS, ReikenS, et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262–1271. doi:10.1038/nm.396126457758
   PubMed Web of Science ®Google Scholar
• ColemanRE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s–6249s. doi:10.1158/1078-0432.CCR-06-093117062708
   PubMed Web of Science ®Google Scholar
• SzadeK, GulatiGS, ChanCKF, et al. Where hematopoietic stem cells live: the bone marrow niche. Antioxid Redox Signal. 2018;29(2):191–204. doi:10.1089/ars.2017.741929113449
   PubMed Web of Science ®Google Scholar
• GdowskiAS, RanjanA, VishwanathaJK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res. 2017;36(1):108. doi:10.1186/s13046-017-0578-128800754
   PubMed Web of Science ®Google Scholar
• WeilbaecherKN, GuiseTA, McCauleyLK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–425. doi:10.1038/nrc305521593787
   PubMed Web of Science ®Google Scholar
• MiglioriniF, MaffulliN, TrivellasA, EschweilerJ, TingartM, DriessenA. Bone metastases: a comprehensive review of the literature. Mol Biol Rep. 2020;47(8):6337–6345. doi:10.1007/s11033-020-05684-032749632
   PubMed Web of Science ®Google Scholar
• LiptonA. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol. 2010;37:S15–S29. doi:10.1053/j.seminoncol.2010.10.00221111244
   PubMed Web of Science ®Google Scholar
• DengX, HeG, LiuJ, et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev. 2014;40(6):730–738. doi:10.1016/j.ctrv.2014.04.00324767837
   PubMed Web of Science ®Google Scholar
• ClezardinP, TetiA. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007;24(8):599–608. doi:10.1007/s10585-007-9112-818008175
   PubMed Web of Science ®Google Scholar
• WippermannB, MössingerE, SchrattHE, BastianL, KrettekC. Diagnostik und Therapie von Knochenmetastasen [Diagnosis and therapy of bone metastases]. Chirurg. 2001;72(5):638–651. doi:10.1007/PL0000260011383084
   PubMed Web of Science ®Google Scholar
• DoschakMR, KucharskiCM, WrightJE, ZernickeRF, UludağH. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol Pharm. 2009;6:634–640. doi:10.1021/mp800236819718808
   PubMed Web of Science ®Google Scholar
• ColeLE, Vargo-GogolaT, RoederRK. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev. 2016;99:12–27. doi:10.1016/j.addr.2015.10.00526482186
   PubMed Web of Science ®Google Scholar
• CrespoL, SanclimensG, PonsM, GiraltE, RoyoM, AlbericioF. Peptide and amide bond-containing dendrimers. Chem Rev. 2005;105(5):1663–1681. doi:10.1021/cr030449l15884786
   PubMed Web of Science ®Google Scholar
• HuangX, El-SayedIH, QianW, El-SayedMA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006;128(6):2115–2120. doi:10.1021/ja057254a16464114
   PubMed Web of Science ®Google Scholar
• ChenJ, WangD, XiJ, et al. Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett. 2007;7(5):1318–1322. doi:10.1021/nl070345g17430005
   PubMed Web of Science ®Google Scholar
• Della RoccaJ, LiuD, LinW. Nanoscale metal-organic frameworks for biomedical imaging and drug delivery. Acc Chem Res. 2011;44(10):957–968. doi:10.1021/ar200028a21648429
   PubMed Web of Science ®Google Scholar
• FéreyG. Hybrid porous solids: past, present, future. Chem Soc Rev. 2008;37(1):191–214.18197340
   PubMed Web of Science ®Google Scholar
• KitagawaS, KitauraR, NoroS. Functional porous coordination polymers. Angew Chem Int Ed Engl. 2004;43(18):2334–2375. doi:10.1002/anie.20030061015114565
   PubMed Web of Science ®Google Scholar
• DuanLN, DangQQ, HanCY, ZhangXM. An interpenetrated bioactive nonlinear optical MOF containing a coordinated quinolone-like drug and Zn(II) for pH-responsive release. Dalton Trans. 2015;44(4):1800–1804. doi:10.1039/C4DT02672A25473930
   PubMed Web of Science ®Google Scholar
• RieterWJ, TaylorKM, AnH, LinW, LinW. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J Am Chem Soc. 2006;128(28):9024–9025. doi:10.1021/ja062744416834362
   PubMed Web of Science ®Google Scholar
• Di NunzioMR, AgostoniV, CohenB, GrefR, DouhalA. A “ship in a bottle” strategy to load a hydrophilic anticancer drug in porous metal organic framework nanoparticles: efficient encapsulation, matrix stabilization, and photodelivery. J Med Chem. 2014;57(2):411–420. doi:10.1021/jm401720224345217
   PubMed Web of Science ®Google Scholar
• TanG, ZhongY, YangL, JiangY, RenF. A multifunctional MOF-based nanohybrid as injectable implant platform for drug synergistic oral cancer therapy. Chem Eng J. 2020;390:124446. doi:10.1016/j.cej.2020.124446
   Web of Science ®Google Scholar
• AdhikariC, DasA, ChakrabortyA. Zeolitic Imidazole Framework (ZIF) nanospheres for easy encapsulation and controlled release of an anticancer drug doxorubicin under different external stimuli: a way toward smart drug delivery system. Mol Pharm. 2015;12(9):3158–3166. doi:10.1021/acs.molpharmaceut.5b0004326196058
   PubMed Web of Science ®Google Scholar
• AyaziH, AkhavanO, RaoufiM, VarshochianR, Hosseini MotlaghNS, AtyabiF. Graphene aerogel nanoparticles for in-situ loading/pH sensitive releasing anticancer drugs. Colloids Surf B Biointerfaces. 2020;186:110712. doi:10.1016/j.colsurfb.2019.11071231846894
   PubMed Web of Science ®Google Scholar
• WangR, ShouD, LvO, KongY, DengL, ShenJ. pH-Controlled drug delivery with hybrid aerogel of chitosan, carboxymethyl cellulose and graphene oxide as the carrier. Int J Biol Macromol. 2017;103:248–253. doi:10.1016/j.ijbiomac.2017.05.06428526342
   PubMed Web of Science ®Google Scholar
• YangX, ZhaiD, SongJ, et al. Rhein-PEG-nHA conjugate as a bone targeted drug delivery vehicle for enhanced cancer chemoradiotherapy. Nanomedicine. 2020;27:102196. doi:10.1016/j.nano.2020.10219632272233
   PubMed Web of Science ®Google Scholar
• YinJJ, PollockCB, KellyK. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15(1):57–62. doi:10.1038/sj.cr.729026615686629
   PubMed Web of Science ®Google Scholar
• HeF, MatsumotoY. Basic and clinical associations between bone and cancer. Immunol Med. 2020;43(3):103–106. doi:10.1080/25785826.2020.175408432301686
   PubMedGoogle Scholar
• RoodmanGD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–1664. doi:10.1056/NEJMra03083115084698
   PubMed Web of Science ®Google Scholar
• MarkovskyE, KoroukhovN, GolombG. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine. 2007;2(4):545–553. doi:10.2217/17435889.2.4.54517716137
   PubMed Web of Science ®Google Scholar
• McMeneminR, MacdonaldG, MoffatL, BissettD. A Phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation. Invest New Drugs. 2002;20(3):331–337. doi:10.1023/A:101622502412112201496
   PubMed Web of Science ®Google Scholar
• MinottiG, MennaP, SalvatorelliE, CairoG, GianniL. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229. doi:10.1124/pr.56.2.615169927
   PubMed Web of Science ®Google Scholar
• SusaM, IyerAK, RyuK, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer. 2009;9:399. doi:10.1186/1471-2407-9-39919917123
   PubMed Web of Science ®Google Scholar
• FazaeliY, AkhavanO, RahighiR, AboudzadehMR, KarimiE, AfaridehH. In vivo SPECT imaging of tumors by 198,199Au-labeled graphene oxide nanostructures. Mater Sci Eng C Mater Biol Appl. 2014;45:196–204. doi:10.1016/j.msec.2014.09.01925491820
   PubMed Web of Science ®Google Scholar
• AkhavanO, GhaderiE. Graphene nanomesh promises extremely efficient in vivo photothermal therapy. Small. 2013;9(21):3593–3601. doi:10.1002/smll.20120310623625739
   PubMed Web of Science ®Google Scholar
• YangK, ZhangS, ZhangG, SunX, LeeST, LiuZ. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010;10(9):3318–3323. doi:10.1021/nl100996u20684528
   PubMed Web of Science ®Google Scholar
• ClarkeB. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3:S131–S139. doi:10.2215/CJN.0415120618988698
   PubMed Web of Science ®Google Scholar
• CarboneEJ, RajpuraK, AllenBN, ChengE, UleryBD, LoKW. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. Nanomedicine. 2017;13(1):37–47. doi:10.1016/j.nano.2016.08.01527562211
   PubMed Web of Science ®Google Scholar
• XuXL, GouWL, WangAY, et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med. 2013;11:303. doi:10.1186/1479-5876-11-30324330728
   PubMed Web of Science ®Google Scholar
• NadarRA, MargiottaN, IafiscoM, van den BeuckenJJJP, BoermanOC, LeeuwenburghSCG. Bisphosphonate-functionalized imaging agents, anti-tumor agents and nanocarriers for treatment of bone cancer. Adv Healthc Mater. 2017;6(8):1601119. doi:10.1002/adhm.201601119
   Web of Science ®Google Scholar
• TerposE, SezerO, CroucherPI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network. Ann Oncol. 2009;20(8):1303–1317. doi:10.1093/annonc/mdn79619465418
   PubMed Web of Science ®Google Scholar
• FornariFA, RandolphJK, YalowichJC, RitkeMK, GewirtzDA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994;45:649–656.8183243
   PubMed Web of Science ®Google Scholar
• MomparlerRL, KaronM, SiegelSE, AvilaF. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976;36:2891–2895.1277199
   PubMed Web of Science ®Google Scholar